ClinicalTrials.gg
Active, not recruitingNCT04168372Updated Nov 12, 2026

Fructose: Substrate, Stimulus, or Both?

An interventional study of High fructose, fructose labeled meal and High fructose, pyruvate labeled meal in Insulin Resistance, Insulin Sensitivity and Pre Diabetes, sponsored by Touro University, California. Active, not recruiting at 1 site in United States. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Touro University, California · Not applicable, Interventional, and Basic science

How we know

Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,118 studies in Insulin Resistance with a site in United States — 117 open to participants now, 149 under way, 2 of them phase 3. Insulin Resistance · United States.

Enrollment
482nd of 936
35 · median 37
Started
2019
with 42 others
No phase
535 of 1,118
62 open now
Primary completion
2027-06
later than 66 of 146 live
Registered
878th of 1,118
by date

Among the 1,118 studies in Insulin Resistance with a site in United States, this one is the 482nd largest by enrollment of the 936 interventional ones that give a count, is one of 43 that started in 2019, is one of 535 with no phase, reaches primary completion later than 66 of the 146 other live ones, and was the 878th registered.

Insulin Resistance

2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

117 of the 1,118 studies in Insulin Resistance with a site in United States are open now. Recruiting first, the newest first:

112 more — sign in →

All 117 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.

This study: 20 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,118 studies in Insulin Resistance with a site in United States, or all of them as a file.
02

Study summary

This objective of this study is to use sensitive methodology under controlled conditions to investigate the mechanisms by which fructose consumption contributes to excess fatty acid synthesis and elevations in blood glucose levels following consumption of meals containing fructose.

03

Conditions studied

  • Insulin Resistance
  • Insulin Sensitivity
  • Pre Diabetes

Keywords

  • Fructose
  • Glucose
  • Lipogenesis
04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 22 to 35 kg/m2
  • Prediabetic ( 5.7% to 6.5%) or hyperinsulinemic (fasting insulin ≥12 µIU/mL) but non-diabetic (fasting glucose \<126mg/dL and HbA1c \< 6.5%) ; or normal control (fasting insulin \<10 µIU/mL, fasting glucose \<100 mg/dL, and HbA1c \< 5.7%)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation within the past six months
  • Type 1 or 2 diabetes mellitus
  • History of liver disease or (AST) and alanine aminotransferase (ALT) 2x the (ULN);
  • Fasting triglyceride or total cholesterol levels above 95th percentile for age and sex;
  • or hematocrit below the lower limit of normal for sex;
  • Report of hepatitis or infection;
  • History of cancer, use of any anti-diabetic medications or hypolipidemic agents in the past six months;
  • History of surgical procedure for obesity;
  • Self-reported change in body weight >5% in the past six months;
  • History of other conditions known to affect insulin sensitivity and lipid metabolism;
  • Known intolerance to acetaminophen or components of the liquid test meals.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    High fructose meal, with fructose label

    2-13C fructose incorporated into a meal with high fructose content

    Other: High fructose, fructose labeled meal

  • Experimental
    High fructose meal, with pyruvate label

    2-13C pyruvate incorporated into a meal with high fructose content

    Other: High fructose, pyruvate labeled meal

  • Experimental
    Low fructose meal, with fructose label

    2-13C fructose incorporated into a meal with low fructose content

    Other: Low fructose, fructose labeled meal

  • Experimental
    Low fructose meal, with pyruvate label

    2-13C pyruvate incorporated into a meal with low fructose content

    Other: Low fructose, pyruvate labeled meal

Interventions

  • OtherHigh fructose, fructose labeled meal

    Liquid meal containing high fructose (16% of energy), labeled with 2-13C fructose

  • OtherHigh fructose, pyruvate labeled meal

    Liquid meal containing high fructose (16% of energy), labeled with 2-13C pyruvate

  • OtherLow fructose, fructose labeled meal

    Liquid meals containing low fructose (6% of energy), labeled with 2-13C fructose

  • OtherLow fructose, pyruvate labeled meal

    Liquid meal containing low fructose (6% of energy), labeled with 2-13C pyruvate

06

What researchers measure

Primary outcomes

  1. Hepatic fractional de novo lipogenesis in triglyceride rich lipoprotein (TRL)

    Measured by the detection of 13C carbons in TRL-palmitate from administered 13C labeled pyruvate or 13C labeled fructose.

    Time frame: 6 hours

  2. Rate of appearance of UDP-glucose

    An estimate of hepatic glycogen flux measured by administration of D1 galactose and acetaminophen

    Time frame: 6 hours

  3. Rate of appearance of blood glucose from gluconeogenesis

    Measured by the dilution method of labeled glucose

    Time frame: 6 hours

Secondary outcomes

  1. Serum triglyceride concentration

    Fasting and postprandial serum triglyceride levels

    Time frame: 6 hours

  2. Serum glucose concentration

    Fasting and postprandial serum triglyceride levels

    Time frame: 6 hours

  3. Serum lactate concentration

    Fasting and postprandial serum lactate levels

    Time frame: 6 hours

  4. Serum insulin concentration

    Fasting and postprandial insulin levels

    Time frame: 6 hours

  5. Serum free fatty acid concentration

    Fasting and postprandial fatty acid levels

    Time frame: 6 hours

  6. Enteral (chylomicron) fractional de novo lipogenesis (DNL)

    Measured by the detection of 13C carbons in chylomicron-palmitate from administered 13C labeled pyruvate or 13C labeled fructose.

    Time frame: 6 hours

  7. Hepatic (VLDL) fractional de novo lipogenesis (DNL)

    Measured by the detection of 13C carbons in VLDL-palmitate from administered 13C labeled pyruvate or 13C labeled fructose.

    Time frame: 6 hours

  8. Extrasplanchnic fructose

    Calculated using total plasma fructose, plasma 2-13C fructose enrichment, and endogenous fructose production

    Time frame: 6 hours

  9. Whole body fructose oxidation

    Measured by 13C atom % excess in exhaled breath, and VCO2 by indirect calorimetry

    Time frame: 6 hours

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Jun 2027, 93 months after the start.

Of 715 non-industry interventional studies with no phase under Insulin Resistance, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 93 months is above that.

Counting every sponsor, half of 755 studies reached it within 21 months; a quarter within 9 and three quarters within 40.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2026 → Jun 2027 and completion Jul 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2019
First posted
Nov 19, 2019
StartActual
Sep 15, 2019
Primary completionEst.
Jun 30, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Jul 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Jun 30, 2027
Nov 12, 2026
Study completion
Jul 20, 2027→Dec 31, 2027
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Dec 31, 2026→Jun 30, 2027
    Study completion Jul 20, 2027→Dec 31, 2027
    + 3 other changes: identifiers, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04168372
Lead sponsor
Touro University, California
Responsible party
Sponsor
First posted
Nov 19, 2019
Start date
Sep 15, 2019
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Jean-Marc Schwarz, PhD
principal investigator · Touro University, California

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion